top-bar-logos

Summary Of Our Research

Transplantation is widely recognized as the treatment of choice for end-stage organ disease in children. Nevertheless, despite significant advances in immunosuppressive therapeutics to prevent acute rejection, long-term graft survival remains suboptimal.

Our research is based on the critical need to develop a greater understanding of immune responses that both promote and inhibit allograft rejection. The laboratory is focused on mechanistic studies that define the state of the alloimmune response as well as an understanding of how the graft itself may dictate the process of inflammation/rejection vs immune evasion/proresolution.

Our studies focus on three broad areas including:

How events within the intragraft microenvironment including leukocyte-endothelial cell interactions promote, sustain, or inhibit T cell activation and allorecognition

Discrete signals and molecular interactions in select populations of T cells that are integral to inflammation resolution

The application of these discoveries into the development of biomarkers and new therapeutics to transform clinical care and improve outcomes following transplantation

Active Projects Include

The Intragraft Microenvironment and the Development of RejectioN

Allograft rejection is associated with persistent mononuclear cell recruitment, endothelial cell activation and proliferation and related biology that enhance effector immune responses. In our previous studies, we provided some of the first evidence that endothelial cells contribute to this pro-inflammatory response.  Our current research is focused on the identity of factors that enable the endothelial cell to shape the intragraft microenvironment either towards local inflammation or local immune evasion and immunoregulation. Ongoing studies focus on regulatory signaling within the vascular endothelial cells that promote the expression of cell surface and/or secreted molecules that are critical for long-term graft survival and/or alloimmune tolerance. Our findings have led to the identity of discrete signals and novel families of molecules within graft endothelial cells that favor immune evasion and local immunoregulation. We are currently testing this biology using sophisticated in vitro cell culture models as well as established pre-clinical in vivo models of transplant rejection or tolerance.

Discrete Signals and Molecular Interactions in Select Populations of T Cells 

Transplantation is widely recognized as the treatment of choice for end-stage organ disease in children. Nevertheless, despite significant advances in immunosuppressive therapeutics to prevent acute rejection, long-term graft survival remains suboptimal.

Neuropilin-2: This project is based on initial observations in which we reported that the binding of semaphorin-3F to its receptor neuropilin-2 results in the inhibition of Akt and mTOR activity. Thus, neuropilin-2-dependant signaling in select immune cell types is likely of great significance in the resolution of inflammation. In our ongoing studies, we have developed novel transgenic mice for the analysis of neuropilin-2 dependent biology in transplant rejection.

 

 

 

DEPTOR: DEPTOR is an evolutionarily conserved and first-in-kind cell intrinsic factor that was discovered as an mTOR-binding partner that regulates cellular activation. In our studies, we identified its expression within CD4+ T cells, and we find that it has striking effects to modulate mTORC1 signaling activity. Following cellular activation, DEPTOR is rapidly phosphorylated and targeted for ubiquitination and degradation, thus removing its negative/regulatory effects on the intracellular signaling/activation response. In ongoing studies, we have reported that sustained levels of DEPTOR expression within CD4+ Foxp3+ T regulatory cells promotes immunoregulation and long-term graft survival following fully MHC mismatched cardiac transplantation. Ongoing studies are addressing whether DEPTOR has additional effects in the immune response, and specifically whether it has biological effects on intragraft cells to regulate alloimmunity.

Clinical Trial Initiatives

There is a great need to study unique alloimmune, genomic, and age-specific biology in pediatric patients following renal transplantation. For many years, Dr. Briscoe’s laboratory has developed and validated biomarkers to identify transplant recipients at risk of acute or chronic rejection. The laboratory has also had a long-standing involvement in innovative clinical trials that include advanced mechanistic studies and biomarker use to evaluate efficacy of novel therapeutics. Currently, Dr. Briscoe is the Principal Investigator of a consortium U01 grant to evaluate the therapeutic efficacy of costimulatory blockade therapeutics following pediatric renal transplantation. Planned collaborative studies will be performed in multiple sites within the US to evaluate the targeting of both cellular and humoral alloimmune responses, immunoregulation as well as pathogen-specific and protective immune responses in trial recipients.